BioSante Pharmaceuticals, Inc. to Present and Participate in Cancer Immunotherapy Panel at the World Vaccine Congress
LINCOLNSHIRE, Illinois (April 19, 2010) – BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will present and separately participate in a cancer immunotherapy panel discussion at the World Vaccine Congress, which will take place April 19-22 in Washington, D.C.
Stephen M. Simes, BioSante’s president & CEO, will speak on Thursday, April 22, 2010 at 10:20 am local time. He will provide an overview of BioSante’s GVAX cancer vaccines which now are in several Phase II clinical trials in various cancer types including leukemia, breast cancer and pancreatic cancer, and have received two FDA orphan drug designations. Immediately following his presentation Mr. Simes will participate in a cancer immunotherapy panel discussion titled: What Lessons are Being Learned From Late Stage Clinical Studies?
The panel discussion will be moderated by Dr. Jeffrey Schlom, Chief, Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH. In addition to BioSante, the other companies on the panel will be Dendreon, GlaxoSmithKline Biologicals, BioVex, Biovest, Vaccinogen and Advaxis.
About the World Vaccine Congress
The Washington event is now in its 10th year and has developed into a highly strategic event for government policy makers, public health organizations, pharmaceutical and biotech organizations and research institutes involved in the development and manufacture of vaccines. The World Vaccine Congress remains the largest North American industry event for vaccine stakeholders. Attendance is expected to be over 450 people from 25 countries.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. BioSante’s lead products include LibiGel® (transdermal testosterone gel) in Phase III clinical development by BioSante under a U.S. Food and Drug Administration (FDA) SPA (Special Protocol Assessment) for the treatment of female sexual dysfunction (FSD), and Elestrin™ (estradiol gel) developed through FDA approval by BioSante, indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, currently marketed in the U.S.
Also in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, licensed to Teva Pharmaceuticals (NASDAQ: TEVA) and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3 billion. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), as a vaccine adjuvant, including for an H1N1 (swine flu) vaccine, and drug delivery. In addition, BioSante will seek opportunities for its GVAX cancer immunotherapies, 2A/Furin and other technologies. Additional information is available online at: biosantepharma.cdmail.biz.
For more information please contact:
Harris D. McKinney, Inc.
For information about participating in the LibiGel clinical studies call or visit the following: